伪异沙蟾毒精 | 17008-69-4

• 物质功能分类: 生物化工 - 提取物
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: 伪异沙蟾毒精
• 中文别名: 沙蟾毒精
• 英文名称: ψ-bufarenogin
• 英文别名: Pseudobufarenogin；5-[(3S,5R,8R,9S,10S,12R,13S,14S,17R)-3,12,14-trihydroxy-10,13-dimethyl-11-oxo-2,3,4,5,6,7,8,9,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]pyran-2-one
• CAS: 17008-69-4
• 化学式: C₂₄H₃₂O₆
• 分子量: 416.514
• InChiKey: SOGONHOGEFLVPE-BHZHDSHXSA-N

物化性质

• 沸点：
  635.8±55.0 °C(Predicted)
• 密度：
  1.349±0.06 g/cm3 (20 ºC 760 Torr)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  30
• 可旋转键数：
  1
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  104
• 氢给体数：
  3
• 氢受体数：
  6

制备方法与用途

概述

蟾蜍表皮腺体的分泌物经过干燥后得到蟾酥，其主要成分是多种蟾蜍二烯内酯类化合物。研究表明，伪异沙蟾毒精在抗肿瘤方面表现出独特的作用机制，值得进一步深入研究。

用途

伪异沙蟾毒精能够抑制血管内皮细胞的增殖、迁移、侵袭及体外成环过程，进而抑制体内肿瘤微血管的形成。因此，它可以用于制备抑制血管新生的治疗药物。

生物活性

伪异沙蟾毒精（Pseudobufarenogin）是从蟾蜍毒素中提取得到的一种物质，其具体生物活性尚不完全清楚。

反应信息

• 作为产物：
  描述：

  沙蟾毒精 在 Alternaria alternata AS 3.4578 作用下， 以 乙醇 为溶剂， 反应 144.0h， 以13%的产率得到3-oxoarenobufagin
  参考文献：
  名称：

  Biotransformation of arenobufagin and cinobufotalin byAlternaria alternata

  摘要：

  The biotransformation of arenobufagin (1) and cinobufotalin (2), isolated from the natural medicine Chan Su, by Alternaria alternata AS 3.4578 was carried out. Incubation of 1 and 2 afforded six metabolites: 3-oxo-arenobufagin (1a), psi-bufarenogin (1b), 3-oxo-psi-bufarenogin (1c), 3-oxo-Delta(4)-derivative of cinobufotalin (2a), 3-oxo-cinobufotalin (2b) and 12 beta-hydroxycinobufotalin (2c). Among them, metabolites 1a, 1c and 2c are new compounds and their structures were characterized on the basis of their spectroscopic data (NMR, MS and IR). Compounds 1, 2, 1b, 2a and 2b were evaluated for their cytotoxicity against HepG2 and MCF-7 human cancer cells, and all of them showed significant inhibitory activities.

  DOI：

  10.3109/10242422.2011.578248

文献信息

• NATURAL COMPOUNDS AND FIBROSIS
  申请人：MEDIZINISCHE HOCHSCHULE HANNOVER (MHH)

  公开号：US20190350923A1

  公开（公告）日：2019-11-21

  The present invention relates to an inhibitor of miR-671-5p for use in a method of preventing or treating fibrosis. Further, the present invention encompasses a kit comprising said inhibitor of miR-671-5p. The present invention also relates to an in vitro method for identifying a compound for preventing or treating fibrosis.
• Biotransformation of arenobufagin and cinobufotalin by<i>Alternaria alternata</i>
  作者：Xing Zhang、Min Ye、Yin-Hui Dong、Hong-Bo Hu、Si-Jia Tao、Guang-Tong Chen、Jun Yin、De-An Guo

  DOI：10.3109/10242422.2011.578248

  日期：2011.3

  The biotransformation of arenobufagin (1) and cinobufotalin (2), isolated from the natural medicine Chan Su, by Alternaria alternata AS 3.4578 was carried out. Incubation of 1 and 2 afforded six metabolites: 3-oxo-arenobufagin (1a), psi-bufarenogin (1b), 3-oxo-psi-bufarenogin (1c), 3-oxo-Delta(4)-derivative of cinobufotalin (2a), 3-oxo-cinobufotalin (2b) and 12 beta-hydroxycinobufotalin (2c). Among them, metabolites 1a, 1c and 2c are new compounds and their structures were characterized on the basis of their spectroscopic data (NMR, MS and IR). Compounds 1, 2, 1b, 2a and 2b were evaluated for their cytotoxicity against HepG2 and MCF-7 human cancer cells, and all of them showed significant inhibitory activities.